menu
    • menu

    Company profile for Saol therapeutics

    NEW Drugs in Dev: 5
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    An estimated 350 million people worldwide struggle with rare diseases, but only about 5% of those diseases have therapies available for their treatment. The development of these treatments –sometimes called “orphan drugs” –face special challenges. Due to the infrequency of patients presenting with these conditions, there is often a lack of understanding and experience within the medical community about managing and tre...
    An estimated 350 million people worldwide struggle with rare diseases, but only about 5% of those diseases have therapies available for their treatment. The development of these treatments –sometimes called “orphan drugs” –face special challenges. Due to the infrequency of patients presenting with these conditions, there is often a lack of understanding and experience within the medical community about managing and treating them. Additionally, drug development costs may lead to funding challenges in the efforts to bring effective therapies to these small patient populations.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Saol therapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1000 Holcomb Woods Parkway Suite 270 Roswell, GA 30076
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://saolrx.com/contact-us/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PCHi

    PCHi

    Not Confirmed

    envelop Contact Supplier

    PCHi

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rare Groups Push for Speed as Makary Defends Strict Stance
    Rare Groups Push for Speed as Makary Defends Strict Stance

    27 Feb 2026

    // BIOSPACE

    https://www.biospace.com/fda/rare-disease-groups-lobby-for-regulatory-expediency-as-makary-defends-rigorous-approach

    BIOSPACE
    27 Feb 2026
    Share Share
    Saol Therapeutics Secures FDA Type A Meeting For SL1009
    Saol Therapeutics Secures FDA Type A Meeting For SL1009

    09 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/saol-therapeutics-has-been-granted-a-type-a-meeting-with-the-fda-to-determine-the-path-forward-for-sl1009-in-pyruvate-dehydrogenase-complex-deficiency-pdcd-302635551.html

    PR NEWSWIRE
    09 Dec 2025
    Share Share
    FDA Issues Complete Response Letter to Saol for SL1009 (DCA)
    FDA Issues Complete Response Letter to Saol for SL1009 (DCA)

    08 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/saol-therapeutics-receives-complete-response-letter-from-fda-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-302548522.html

    PR NEWSWIRE
    08 Sep 2025
    Share Share
    Saol Therapeutics Poster at UMDF Mitochondrial Med. Conf. 2025
    Saol Therapeutics Poster at UMDF Mitochondrial Med. Conf. 2025

    19 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/saol-therapeutics-announces-poster-presentation-at-the-umdf-mitochondrial-medicine-2025-conference-302486196.html

    PR NEWSWIRE
    19 Jun 2025
    Share Share
    Saol Announces Clinical Milestones in Development Program
    Saol Announces Clinical Milestones in Development Program

    17 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/saol-therapeutics-announces-major-clinical-milestones-across-multiple-development-programs-302431503.html

    PR NEWSWIRE
    17 Apr 2025
    Share Share
    Saol's SL1009 NDA Accepted for Pyruvate Dehydrogenase Deficiency
    Saol's SL1009 NDA Accepted for Pyruvate Dehydrogenase Deficiency

    28 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/saol-therapeutics-announces-fda-acceptance-of-new-drug-application-for-sl1009-for-treatment-of-pyruvate-dehydrogenase-complex-deficiency-302361297.html

    PR NEWSWIRE
    28 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search